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Abstract
Androgen receptor (AR) mediated signalling is necessary for normal development of the
prostate gland and also drives prostate cancer (PCa) cell growth and survival, with many
studies showing a correlation between increased receptor levels and therapy resistance
with progression to fatal castrate recurrent PCa (CRPC). Although it has been held for some
time that the transcription factor Sp1 is the main stimulator of AR gene transcription, com-
prehensive knowledge of the regulation of the AR gene remains incomplete. Here we
describe and characterise in detail two novel active regulatory elements in the 5’UTR of the
human AR gene. Both of these elements contain overlapping binding sites for the positive
transcription factor Sp1 and the repressor protein pur-α. Aberrant cell signalling is charac-
teristic of PCa and the transcriptional activity of the AR promoter in PCa cells is dependent
upon the relative amounts of the two transcription factors. Together with our corroboration
of the dominant role of Sp1, the findings support the rationale of targeting this transcription
factor to inhibit tumour progression. This should be of particular therapeutic relevance in
CRPC where the levels of the repressor pur-α are reduced.
Introduction
Prostate cancer (PCa) is the second most prevalent cancer in men and constitutes the second
leading cause of male cancer deaths in Western nations and the sixth worldwide respectively
[1]. In addition, the incidence of PCa is rising in virtually all countries with the rate of new
cases expected to double by 2030 to 1.7 million resulting in 500,000 additional deaths [2].
The growth and differentiation of normal prostate epithelial cells, as well as development
and progression of PCa, are driven by androgen signalling which is mediated by the androgen
receptor (AR) [3]. Therefore, inhibition of AR function by androgen deprivation therapy
(ADT) using antagonists or abatement of testicular or intratumoural androgen synthesis con-
stitutes the principal procedure for tackling advanced and metastatic PCa [4–6]. Initially, most
patients experience significant improvement and remission, but the cancer invariably evolves
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to become independent of circulating androgens and is referred to as castrate resistant PCa
(CRPC) [7]. This late, metastatic stage is usually fatal and represents the greatest challenge for
the development of new, efficacious therapies [8]; necessitating multiple AR-targeted regimens
(reviewed in [9]). Crucially, CRPC tumours remain dependent upon AR signalling; exemplified
in both androgen sensitive (AS) and CRPC cells where decreased AR expression induces a con-
comitant loss of cell viability [10].
The androgen receptor functions as an androgen-activated transcription factor that binds to
androgen response elements (AREs) [4] in promoters and distal enhancers (86% to 95% of
AREs [11]). The transactivation capability of the receptor is modulated by interactions with an
ever-growing list of coregulators and transcription factors (reviewed in [12]) that act on the
receptor itself or alter the chromatin environment. For example, the pioneer transcription fac-
tors FOXA1 and GATA2 promote an open chromatin structure that facilitates AR binding,
and genome wide studies show co-localisation of binding sites for these three factors [13,14].
GATA2 plays a particularly important role because as well as increasing AR binding to enhanc-
ers, it participates in chromatin looping and directly upregulates AR gene expression [13,14].
Elevated levels of GATA2 in PCa correlate with high Gleeson scores, and reduced activity
through dampened expression [13,14] or inhibition of GATA2 occupancy at AREs with the
isoflavone curcumin [15] result in lower PCa cell proliferation.
The majority of CRPC tumours overexpress the receptor [16–19] with clonal selection exac-
erbating the problem [20]. The elevated levels of AR permit binding to chromatin in 100-fold
lower concentration of ligand than normal [21] and the aberrant AR-driven transcriptional
programme in CRPC tumours allows cells to grow in low concentrations of androgen [22] or
the apparent absence of hormone [23–25], thereby abrogating ADT [26] and treatment with
abiraterone [20].
In humans, the AR gene spans approximately 180 kbp of the X-chromosome (Xq11.2-q12)
and gives rise to a transcript of 4.3 kb that includes an uncommonly long 5’ untranslated region
(5’UTR) of 1.1 kb. The promoter lacks TATA and CCAAT boxes and, in common with many
TATA-less genes, transcription is driven primarily by binding of the ubiquitously expressed
zinc finger transcription factor, Specificity Protein 1 (Sp1) to GC box regulatory elements. The
core promoter lies between -74 and +87 bp [27] and active GC boxes have been confirmed at
-46 to -41 bp as well as in the 5’UTR at +429 and +442 bp [27–29]. Sp1-driven expression of
the AR gene is facilitated by an approximately 90 bp stretch of homopurine/homopyrimidine
immediately upstream of the promoter (-150 to -60 bp) that provides an abundant supply of
the transcription factor to bind to the core promoter [30]. Once bound to the promoter, Sp1
associates directly with the TATA-binding protein and TBP-associated factor 4 (TAF4) [31] to
establish the initiation complex. In addition, Sp1 can form multimers and multiple stacked tet-
ramers providing numerous docking sites for a variety of other proteins to regulate transcrip-
tion both directly and through histone acetylation and chromatin remodelling (reviewed in
[32]). In addition to the upregulatory GC boxes, the 5’UTR region encodes several inhibitory
regulatory elements including a composite NF-κB, B-myb binding site [33], an negative ARE
[34] and an Androgen Receptor Suppressor (ARS) [35] that binds pur-α and hnRNP-K on
opposite strands of the DNA [36].
The AR clearly represents the Achilles’ heel of prostate cancer yet the current primary treat-
ment involving androgen antagonists has limitations and also leads to expression of an alterna-
tive AR-driven transcriptome with variable PCa outcomes [37]. A much more efficacious
approach would be to reduce AR activity through reduced expression or interference with
essential transcription cofactors e.g. a small molecule inhibitor of GATA2 has proven to be
effective [13]. Both approaches depend upon detailed knowledge of the interactions of the mul-
tiple transcription factors and regulatory elements involved in AR expression. Therefore, as the
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transcription factor Sp1 is generally considered to be a major stimulator of AR gene expression,
we have studied Sp1 function at the immediate promoter and 5’UTR of the human AR gene. In
this report we describe two novel active regulatory elements in the human AR 5’UTR that both
contain overlapping binding sites for positive and negative transcription factors. The transcrip-
tional outcome in PCa cells is dependent upon the relative amounts of stimulatory Sp1 and
inhibitory pur-α. The findings also substantiate the dominant role of Sp1 in driving AR expres-
sion and thus reinforce the rationale of targeting this transcription factor, as this action will
promote binding of competing pur-α and inhibit tumour progression. Lastly, the regulatory
elements exhibit very poor evolutionary conservation illustrating the distinctive nature of
human AR gene regulation.
Materials and Methods
Cell culture
Human prostate carcinoma cell lines LNCaP and DU145 were obtained from The European
Collection of Cell Cultures and the American Type Culture Collection respectively. DU145
were grown in DMEM while LNCaP were maintained in RPMI containing 1 mMNa pyruvate
and 10 mMHEPES. All media were supplemented with 10% foetal bovine serum (PAA) and
maintained at 37°C without antibiotics in a humidified atmosphere containing 95% air and 5%
CO2.
Western blotting
Cell extracts were prepared from LNCaP and DU145 cells, and western blots performed as
detailed previously [38]. Human Sp1, pur-α, hnRNP-K, and GAPDH were detected using anti-
bodies ab13370, ab79936, ab52600 and ab36840 (all from Abcam) at dilutions of 1:6,000,
1:60,000, 1:17,000 and 1:12,500 respectively. Anti-AR from Santa Cruz Biotechnology (sc–
7305) was used at 1: 100 dilution. Antigen-antibody complexes were detected using horserad-
ish peroxidase-conjugated anti-rabbit IgG secondary antibody (Sigma) as previously described.
Integration analysis of western blots was carried out using Image J software.
RT-PCR
LNCaP cells were treated with DMSO or 50 nMmithramycin A (Sigma) for 24 hours. Extrac-
tion of RNA and RT-PCR for AR and GAPDHmRNA were carried out as described previously
[34].
Plasmids and site directed mutagenesis
Mutations of potential regulatory elements were introduced into plasmid phAR1.6Luc, in
which luciferase expression is driven by 1.6 kbp of the promoter and 5’UTR of the human
androgen receptor gene (between -741 and +842 bp) [34], using two methodologies. Base sub-
stitutions were created using the QuikChange II Mutagenesis kit (Agilent Technologies) using
the oligonucleotides listed in Table A in S1 File, along with their reverse complements. Deletion
mutations were made using the In-Fusion Advantage PCR cloning system from Clontech
using the oligonucleotides listed in Table B in S1 File. Both protocols were performed accord-
ing to the manufacturer’s protocol and the integrity of all constructs was confirmed by DNA
sequencing.
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Transfection and Luciferase reporter gene assays
Twenty four-well plates were seeded with LNCaP or DU145 cells at a density of 5 x 104 cells/
cm2 and 1.2 x 104 cells/cm2 respectively. The cells were cultured in complete medium for 24 h,
then transfected with 440 ng/well of firefly luciferase reporter plasmid using JetPEI polyethyle-
nimine (Polyplus Transfection) according to the manufacturer’s protocol. After 24 h, the
medium was replaced and the cells were cultured for a further 24 or 48 h.
Plasmid transfection was performed in at least triplicate and luciferase activity was mea-
sured in duplicate or triplicate by using a GloMax 96 Microplate luminometer (Promega) and
normalised for protein concentration as previously described [38].
Preparation of nuclear extracts
Nuclear extracts were prepared from DU145 cells in the presence of protease inhibitors (com-
plete protease inhibitor cocktail from Roche plus 1.0 mM PMSF) and protein phosphatase
inhibitors (5 mM β-glycerophosphate and 100 μM activated Na3VO4) using the method of
Dignam et al [39].
Electrophoretic mobility shift assays (EMSAs)
Either 10 μg LNCaP cell nuclear extract or 120 nM purified recombinant human Sp1 protein
(Active Motif) were incubated with 20 fmol biotin 3’ end-labelled double stranded DNA oligo-
nucleotides using previously described conditions [34]. The forward sequences of the oligonu-
cleotides were: Sp1-1, 5’-CGGCCCGGTGGGGGCGGGACCCGACTCGCA–3’; ARS, 5’-TC
TCCACCCCGCCTCCCCCCACCCTGCCTT–3’; and Sp1-3, 5’-TTCTCCCCACCCGCCCCC
CCGCCCCCGTCG–3’. An unlabelled oligonucleotide of a consensus Sp1 regulatory element,
Sp1 cons, 5'-ATTCGATCGGGGCGGGGCGAGC–3' was added 15 min prior to the labelled
probe. For supershift assays the antibodies ab13370 and ab52600 (Abcam) against human Sp1
and hnRNP-K respectively were added 15 min prior to the addition of labelled probe.
The resulting DNA:protein products were resolved in cooled 6% nondenaturing polyacryl-
amide gels run in 0.5x TBE buffer, pH 8.3 (45 mM Tris-borate, 1 mM EDTA) and detected
using Pierce LightShift Chemiluminescent reagents (Thermo Scientific) according to the man-
ufacturer’s protocol. Figures were compiled using autorads of EMSA gels with the order of
lanes within some gels being altered to aid clarity and facilitate comparisons. Digital integration
of the DNA:protein complexes was carried out using a Vilber Loumat Fusion SL cooled CCD
sensor with care being taken to ensure that no pixel saturation occurred.
Chromatin immunoprecipitation (ChIP) assay
A detailed account of the ChIP methodology has been presented previously [34]. In brief,
LNCaP cells were transfected with the relevant phAR1.6Luc-based plasmid and grown in the
usual manner. Cells were fixed in 1% formaldehyde for 10 min at 37°C and nuclei were pre-
pared. Chromatin and plasmid were digested with 200 units HphI (NEB) for 20 min at 37°C;
followed by lysis and the removal of insoluble debris by centrifugation. The supernatant was
diluted in ChIP buffer and precleared using Protein-G and Protein-A Dynabeads (Life Tech-
nologies). Samples of cleared lysates were retained as input (IP) and the remainder was incu-
bated with antibodies against either Sp1 (07–645, Millipore) or IgG. Immunocomplexes were
collected by magnetisation, washed twice each with: low salt; high salt; LiCl and TE buffers, fol-
lowed by elution. DNA-protein cross-links were reversed with NaCl at 65°C and DNA purified.
Isolated DNA was quantified by semi-quantitative log phase PCR and resolved by agarose gel
electrophoresis in TAE buffer. The forward (F) and reverse (R) primers were: ARS-F, 5’-
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GCTGCTAAAGACTCGGAGGA-3’; ARS-R, 5’-CTGAGAGTAGCCGACTGAGG-3’; Sp1-
3-F, 5’-CCCGAGTTTGCAGAGAGGTA-3’ and Vect-R, 5’-TCTTCCATGGTGGCTT-
TACC-3’.
Statistical analysis
The statistical significance of differences in data sets of DNA:protein complex formation in
EMSA experiments was determined using two way ANOVA and paired t-test analysis of vari-
ance was employed for all other comparisons between complementary data.
Results
The human AR gene 5’UTR contains two regions with overlapping
regulatory elements
Examination of the human AR gene encoding the 5’UTR region of the transcript (Fig 1A)
revealed a potential Sp1-binding GC box (+328 to +332 bp) that was found to lie within the
previously described Androgen Receptor Suppressor (ARS) sequence [35] (Fig 1B). The first
example of an ARS regulatory element that can bind the ubiquitously expressed protein pur-α
was described in the mouse AR gene 5’UTR over 400 bp downstream from the corresponding
human sequence [40]. As both GC boxes and ARS sites have high GC content, the possibility
of other examples of these two regulatory elements overlapping was investigated further.
Although binding of pur-α is sequence specific with a preference for repeats of (GGN), there is
no clear consensus recognition sequence, therefore, the region of the mouse ARS protected
from DNase I digestion was used to search for other possible sites in the human 5’UTR. A
region of the human 5’UTR, distal to the ARS sequence, possessing 85% identity was detected
(Fig 1C) which is greater than the 70% identity seen with the same probe and the established
human ARS (S1A Fig). Use of the defined mouse ARS sequence [41] produced a similar finding
with 75% identity which, again, was greater than the value of 67% for the human ARS (S1B and
S1C Fig) respectively. The potential novel suppressor region overlapped the Sp1-3 regulatory
element that is known to harbour two active GC boxes [29]. This raised the intriguing possibil-
ity that these two regions can act to either stimulate or reduce AR expression.
Multiple alignments of the equivalent regions of the human AR gene 5’UTR in 11 other spe-
cies using publically available DNA sequences (Fig 2) showed that both sequences are poorly
conserved. The ARS region is present only in primates and the sequence in chimpanzee, which
diverged from humans 6.6 million years ago [42], has perfect homology with human. Further-
more, and over the span of 42.2 million years from the divergence of humans and marmoset,
the most diverged primate examined, the majority of sequences show only a few nucleotide
substitutions. The Sp1-3 region displayed even less homology with only chimpanzee sharing
both GC boxes with humans. For both regions of interest, non-primate species possessed very
low levels of homology with human, and no equivalent sequences were found in avian or
piscine species (data not shown). In addition, the mouse ARS region is extremely poorly con-
served and no pur-α binding sequence has been found in the equivalent genomic region of
other animals including the closely related rodent; the rat (S2 Fig).
The GC box is the principal Sp1 binding site in the human AR promoter
Initial experiments examined the effect of the Sp1 antagonist, mithramycin A, on the endoge-
nous AR gene in LNCaP cells. A mithramycin A dose dependent reduction in AR protein levels
was observed (Fig 3A) with a concentration of 50 nMmithramycin A being used in subsequent
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Fig 1. Regulatory elements in human AR 5’UTR. (A) Diagrammatic representation of the human AR gene
5’UTR and immediate proximal promoter showing the principal regulatory elements and the regions under
study. Bent arrow indicates the transcriptional start site (+1) and ATG with solid arrow show the start of
translation. (B) Potential GC box (green dashed box) within the confirmed human ARS regulatory element
(blue underlined). (C) Alignment of the human AR 5’UTR and the mouse AR 5’UTR suppressor element
protected from DNase I digestion [40] (blue underlined) with the confirmed human GC boxes (green solid
box). Homologous sequences are indicated by vertical lines.
doi:10.1371/journal.pone.0139990.g001
Fig 2. Multiple genome alignments of the AR 5’UTR. The regions of the hAR gene 5’UTR under investigation were compared to those of the indicated
placental species. (A) the ARS (blue box), and (B) the Sp1-3 regulatory element (green box). Differences from the human sequence are indicated by bold,
underlined font.
doi:10.1371/journal.pone.0139990.g002
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experiments. RT-PCR studies confirmed that the decrease in AR protein levels correlated with
reduced transcription (Fig 3B).
While it has long been held that the transcription factor Sp1 is the main driver of expression
of the TATA box-lacking human AR gene, the relative importance of the GC box (Sp1-1; -45
to -40 bp) in the core promoter remains unclear with deletion studies suggesting that it is either
essential [27] or does not play a significant role [43]. Mutation of the GC box in the phAR1.6-
Luc luciferase reporter plasmid [34] that contains a 1.6 kbp section of the hAR promoter and
5’UTR between positions -741 bp to +842 bp led to a 80% reduction in luciferase expression in
transfected androgen responsive LNCaP cells (Fig 3C). Similarly, a 46% reduction was
observed with the androgen non-responsive PCa cell line DU145 (data not shown). Together,
these assays demonstrated that the core promoter GC box, and Sp1 binding, play a prominent
role in the expression of AR mRNA and protein. Importantly, the mutated reporter plasmid
remained susceptible to inhibition by mithramycin A (Fig 3C), thus confirming that Sp1-me-
diated upregulation of the AR gene occurs at sites other than the GC box.
The 5’UTR overlapping regulatory elements can up- or downregulate
promoter activity
In order to elucidate the functional activity of other potential regulatory elements under study,
further mutations were introduced into the phAR1.6Luc luciferase reporter plasmid. Transfec-
tion experiments were performed using both androgen responsive, LNCaP and non-respon-
sive, DU145 PCa cell lines, that were cultured in complete medium to ensure that all cell
Fig 3. Effect of mithramycin A on ARmRNA and protein expression. LNCaP cells were incubated with mithramycin A for 24 h and then assayed. (A)
Western blot analysis with the relative values of AR/GAPDH shown below. (B) RT-PCR of AR and GAPDHmRNA. LNCaP cells were transfected with
phAR1.6Luc (WT) or phAR1.6Luc-ΔCG and treated with DMSO or 50 nMmithramycin A for 24 hours and luciferase activity was measured. Data represent
the means ± SD of at least three independent experiments and the statistical significance of the indicated comparisons are: * p<0.05; ** p<0.01 and ***
p<0.001.
doi:10.1371/journal.pone.0139990.g003
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signalling pathways that are dependent on media components (growth factors and hormones),
were functional.
In order to establish the role of Sp1 binding to the potential GC box in the ARS (+322 to
+345 in the 5’UTR), base substitutions were introduced to create reporter phAR1.6Luc-
UTRm1 that resulted in reductions of expression of 29% and 13% in DU145 and LNCaP cells
respectively (Fig 4A and 4B) confirming an active role for this novel GC box in upregulating
AR expression. Conversely, this region of the 5’UTR has been shown to act as a negative regula-
tory element through the binding of the transcription factor pur-α that has been reported to be
disrupted under EMSA conditions by the inclusion of a pair of two-base substitutions [35] and
these were used to prepare reporter phAR1.6Luc-UTRm2. However, using this reporter tran-
scriptional activity was reduced by 36% and 20% in DU145 and LNCaP respectively rather
than increased (Fig 4B) as might be predicted upon release of an inhibitor. Inspection of the
sequence changes produced by the mutation reveals that the guanine and cyctosine in the cen-
tre of the putative GC box were replaced by adenine in a manner analogous to the Sp1-specific
mutation in phAR1.6Luc-UTRm1. Therefore, loss of Sp1 binding in this regulatory element is
the dominant outcome, providing further evidence that the putative GC box can actively upre-
gulate AR expression. In the likelihood that the substitution mutation of the ARS region was
insufficient to prevent pur-α and hnRNP-K binding under physiological conditions, the entire
regulatory element was deleted to create phAR1.6Luc-UTRΔm1. In this instance, promoter
activity was upregulated by 1.27 and 1.67 fold in DU145 and LNCaP respectively (Fig 4B) with
the difference between the two cell lines being significant (p<0.01).
Analogous mutations were also introduced into the third regulatory sequence of interest
(+423 to +446). Firstly, the two GC boxes in Sp1-3 were mutated either individually (phAR1.6-
Luc-UTRm3 and phAR1.6Luc-UTRm4) or together (phAR1.6Luc-UTRm5). Luciferase activ-
ity revealed that disruption of the GC boxes resulted in significant decreases in promoter
stimulation. The two single mutations decreased transcriptional activity by 42% and 29% in
DU145 cells and by 29% and 17% in LNCaP cells, and the double mutation displayed reduc-
tions of 34% and 16% in the two cell lines respectively (Fig 4C). Again, the decreases in pro-
moter activity were greater in DU145 than LNCaP. The effects of the mutations were not
cumulative as might be expected from two overlapping binding sites. In a manner similar to
that seen with the +322 to +345 region, base substitution mutation of the potential overlapping
negative regulatory element in phAR1.6Luc-UTRm6 produced losses of transcriptional activity
of 9% and 4% in DU145 and LNCaP respectively (Fig 4C). These values were less those seen
with the +322 to +345 region described above, however, they were consistent with the sequence
changes having only a minor impact on the Sp1 binding sites. Deletion of the entire potential
negative regulatory element in phAR1.6Luc-UTRΔm2 led to 1.18 and 1.50 fold upregulation of
transcriptional activity in DU145 and LNCaP respectively (Fig 4C). As with the phAR1.6Luc-
UTRΔm1 deletion mutation, the increase in promoter activity was significantly greater in
LNCaP than DU145.
The binding characteristics of the 5’UTR overlapping regulatory
elements
The possibility that Sp1 binds to all three regions under study was examined by electrophoretic
mobility shift assays (EMSAs). In initial experiments, purified recombinant human Sp1 protein
was incubated with the labelled oligonucleotide probes containing either the primary GC
box (Sp1-1), the potential novel Sp1 binding site in the ARS region or Sp1-3. Electrophoretic
resolution of the resulting products with all three labelled probes showed a single high
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Fig 4. Effect of mutations on transcriptional activity. (A) Schematic diagram of the luciferase reporter construct phAR1.6Luc driven by 1.6 kbp of the hAR
promoter and 5’UTR with potential transcription factor binding to the regions of interest. Sp1-3 contains two Sp1 binding sites. (B and C) The indicated PCa
cell lines, cultured in complete medium, were transfected with either phAR1.6Luc containing theWT sequence (black bars) or the mutated version (grey bars)
shown above each chart. Luciferase data represent the means ± SEM of at least three independent experiments and the statistical significance of the
indicated comparisons are: * p<0.05; ** p<0.01 and *** p<0.001.
doi:10.1371/journal.pone.0139990.g004
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molecular weight DNA:protein complex near the top of the gel (Fig 5A, lanes 2–4) consistent
with Sp1 having a molecular weight of 95 kDa.
Incubation of nuclear extract prepared from the prostate cancer cell line DU145 with either
Sp1-1, ARS or Sp1-3 oligonucleotides produced several bands with virtually identical electro-
phoretic motilities (Fig 5B, lanes 1, 4 and 6 respectively). The binding of Sp1 was confirmed in
all instances by the addition of anti-Sp1 antibody which produced a supershift with the Sp1-1
oligonucleotide and greatly diminished assembly of a high molecular weight DNA:protein
complex with both ARS and Sp1-3 (Fig 5B, lanes 2, 5 and 7 respectively), while preimmune
serum had no effect (Fig 5B, lane 3). Different outcomes of incubation with anti-transcription
factor antibody can occur in EMSA analyses e.g. CREB-1 to CRE sites in the human insulin
and somatostatin promoters [44], due to several factors including: the strength of binding to
the DNA; the spatial/conformational organisation of the protein on regulatory elements, the
orientation of DNA adjacent to the consensus and the presence of bound cofactors.
Addition of mithramycin A, which interferes with binding of Sp1 to its regulatory element
[45], greatly reduced formation of the high molecular weight complexes with all three oligonu-
cleotides (Fig 5C, compare lanes 1 and 2, 3 and 4, and 5 and 6). Similarly, preincubation with
excess unlabelled oligonucleotide containing the consensus Sp1 binding sequence virtually
Fig 5. Binding of Sp1 to the AR gene promoter and 5’UTR sequences. Purified Sp1 protein (panel A) or
nuclear extract from DU145 cells (panels (B) to (D)) were incubated with the labelled oligonucleotide probes
indicated below each gel and the products resolved by electrophoretic mobility shift analysis. Additions are
shown above the gels and were: Ab, antibody; PI, pre-immune serum; Mith, mithramycin; Sp1 cons,
consensus Sp1 oligonucleotide. Competing unlabelled oligonucleotides (100 fold molar excess) or immune
sera were added prior to addition of probe. EMSAs are representative of at least 3 independent experiments.
(A) The indicated labelled probes were incubated with purified Sp1 protein except in lane 1 which had no
addition. Black arrow indicates Sp1-DNA complex. (B) Anti-Sp1 antibody was added as indicated, and the
complex absent after incubation with antibody is indicated by the arrow. (C) Mithramycin (120 nM) was added
to indicated lanes and the complex depleted after incubation with the drug is indicated by the solid arrow. (D)
Unlabelled competing oligonucleotide encoding Sp1 consensus binding site was added as shown.
doi:10.1371/journal.pone.0139990.g005
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eliminated all DNA:protein complex formation (Fig 5D, compare lanes 1 and 2, 3 and 4, and 5
and 6). Together, these results confirm binding of Sp1 to all three GC box-containing
sequences, supporting the conclusions from reporter gene experiments (Fig 4). Further, the dif-
ference in results seen with the oligonucleotides for the Sp1-1 site in the core promoter in com-
parison to the ARS and Sp1-3 sites, which displayed apparent lower affinity for natural Sp1,
different outcomes upon incubation with anti-Sp1 antibody and lower mutation-induced
reduction in luciferase assays (Fig 4), suggested that binding of Sp1 to the core promoter GC
box was stronger than to the 5’UTR.
The transcription factor pur-α binds preferentially to guanine-rich single stranded DNA or
the equivalent sequences in double stranded DNA. Incubation of nuclear extract with either
the double stranded or the G-rich single reverse strand of the ARS and Sp1-3 probes yielded
quite dissimilar results. Both of the single stranded probes produced a DNA:protein complex
(denoted by open arrow) that migrated slightly ahead of Sp1:DNA and other high molecular
weight complexes typically seen with the double stranded probe (Fig 6A). Consistent with the
ability of pur-α to also bind dsDNA, both the ARS and Sp1-3 double stranded oligonucleotides
produced a faint DNA:protein complex that migrated in a very similar position to the product
seen with the single stranded probes. Importantly, the DNA:protein complex formed with the
G-rich strand of Sp1-3 behaved in an identical manner to that of the equivalent ARS oligonu-
cleotide which is known to bind pur-α [36]. Interestingly, pur-α binds DNA as dimers and
multimers [46] which would survive the non-denaturing conditions of EMSA resulting in the
apparent high molecular weight migration characteristics of the DNA:protein complexes. The
commercial anti-pur-α antibody failed to elicit an effect and the purified protein is not avail-
able. Nevertheless, the complementary cytosine-rich forward strands of the ARS and Sp1-3 oli-
gonucleotides completely failed to produce the DNA:protein complex confirming the
specificity of binding to the G-rich strand (Fig 6B; compare lanes 1 and 7, and 4 and 8).
The ubiquitous protein hnRNP-K, which binds to cytosine-rich single stranded RNA and
DNA, also binds to the ARS in the hAR 5’UTR [36]. The binding of hnRNP-K to the C-rich
forward strand of both the ARS and Sp1-3 sites was confirmed using anti-hnRNP-K antibody
and the results are shown in Fig 6B. In both instances, a single DNA:protein complex was
formed that migrated well ahead of the one seen previously with the G-rich reverse strand.
Addition of preimmune serum had no effect on the formation of the DNA:protein complex,
however, anti-hnRNP-K antibody greatly impeded the binding of the protein to the oligonucle-
otide probes.
Sp1 binds to both 5’UTR regulatory elements
In order to further validate the protein-DNA interactions, ChIP assays were undertaken to
examine Sp1 binding to the two regions of interest in the hAR 5’UTR. The usual method of
preparing chromatin for ChIP analysis involves sonication, however, as the ARS and Sp1-3 reg-
ulatory elements are only 100 bp apart, this methodology does not permit investigation of each
of these regions in isolation. Therefore, restriction enzyme digestion of chromatin was
employed instead. The only commercially available enzyme that cut the DNA between the dif-
ferent Sp1 binding sites without complications from possible CpG methylation in the very high
GC rich hAR promoter and 5’UTR was HphI. As commercially available preparations of HphI
were not of high enough concentrations to yield sufficient levels of solubilised nuclear chroma-
tin, LNCaP cells were transiently transfected with phAR1.6Luc (WT) or phAR1.6Luc-
UTRΔm1. The plasmids were digested with HphI and the solubilised DNA was precipitated
using anti-Sp1 antibody. Fig 7 depicts the hAR 5’UTR along with the cleavage sites for HphI
and the relative positions of the oligonucleotides used for semi-quantitative PCR amplification.
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The Sp1-3 region served as a positive control and anti-Sp1 antibody, but not preimmune Ig
immunoprecipitated both the ARS and Sp1-3 regions of the 5’UTR, confirming that Sp1 binds
to the ARS (Fig 5B). Conversely, phAR1.6Luc-Δm1, in which the ARS regulatory element had
been deleted, was not precipitated by anti-Sp1 antibody. This result also indicated that the
action of the antibody was specific.
Fig 6. The AR 5’UTR possesses overlapping regulatory elements.Nuclear extract from DU145 cells
were incubated with the labelled oligonucleotide probes indicated below each gel and the products resolved
by electrophoretic mobility shift analysis. Additions are shown above the gels and were: Ab, antibody; PI, pre-
immune serum. EMSAs are representative of at least 3 independent experiments. (A) Either double stranded
probes or single stranded oligonucleotides of the reverse strand were incubated with nuclear extract and
protein-DNA complexes resolved: black arrow indicates Sp1 and open arrow indicates pur-α binding
respectively. (B) Forward and reverse single stranded labelled oligonucleotides of the regulatory elements
were incubated with nuclear extract. Anti-hnRNP-K antibody was included where indicated and
hnRNP-K-DNA complexes indicated by grey arrow and open arrow indicates pur-α binding.
doi:10.1371/journal.pone.0139990.g006
Fig 7. ChIP analysis confirms binding of Sp1 to 5’UTR ARS. (A) Line diagram (not to scale) of the hAR
5’UTR showing the recognition sites of the restriction endonuclease HphI used to digest plasmid, plus the
forward (F) and reverse (R) primers (solid arrows) used for ChIP semi-quantitative PCR. Oligonucleotide
Vect-R was specific for the plasmid vector sequences, and the bent arrow indicates the transcriptional start
site. (B). Representative agarose gels of PCR amplified DNA immunoprecipitated with anti-Sp1 antibody in
which the order of some lanes have been altered to aid clarity and facilitate comparisons; IP, input sample; Ig,
pre-immune rabbit IgG; Ab, anti-Sp1 antibody.
doi:10.1371/journal.pone.0139990.g007
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The relative amounts of Sp1 and pur-α influence the activity of the
overlapping regulatory elements
The possibility that the different outcomes of mutation of the Sp1 and pur-α binding sites in
DU145 and LNCaP could be directed by aberrant cell signalling was examined by comparing
the levels of the associated transcription factors using western blot analysis. Relative to the
house-keeping enzyme GAPDH, DU145 cells had 2.2 fold higher levels of Sp1 in comparison
to LNCaP while the converse occurred in the case of pur-α with LNCaP cells having 3.9 fold
higher levels in comparison to DU145 (Fig 8). These results are in agreement with other reports
that pur-α is decreased at both the protein and mRNA levels in PC3 and DU145 compared to
LNCaP cells [47], while the levels of Sp1 were elevated in DU145 compared with LNCaP. No
significant difference was noted in the levels of hnRNP-K between the two PCa cell lines.
Western blot analyses reveals striking differences in the relative amounts of Sp1 and pur-α
in the two PCa cell lines. The ratios of transcription factors Sp1 to pur-α are consistent with
the promoter activity observed in the luciferase assays. Mutation of the dominant GC box in
the promoter (Sp1-1), which binds only Sp1 and not pur-α, reduced transcriptional activity to
a significantly greater degree in LNCaP than DU145 which is compatible with the former cell
type having much lower levels of Sp1 and thus having lower capacity to compensate for the
impaired binding to the regulatory element in the promoter, or through compensatory binding
to GC boxes in the 5’UTR. A different scenario was evident at the 5’UTR ARS and Sp1-3 sites
where stimulatory Sp1 and inhibitory pur-α were in competition. In both instances, mutation
of the Sp1-binding GC boxes resulted in a loss of activity implying that, in the cells used in the
studies, the balance of up—and downregulation tended towards Sp1 stimulation. The effects of
mutation were more pronounced in DU145, which had an almost 9 fold greater ratio of Sp1 to
pur-α, whereas in LNCaP with higher levels of pur-α the upregulatory role of the two 5’UTR
WT regions would have been lower. Similarly, complete deletion of the regions to ensure no
binding of either Sp1 or pur-α led to significantly greater release of inhibition in pur-α-rich
LNCaP than in DU145.
Discussion
High levels of androgen receptor expression are often a crucial factor in driving progression of
PCa leading to resistance to ADT and drug regimes. In order to control AR expression, a more
detailed understanding of the intricacies of human AR gene regulation is of fundamental
importance. Consequently, this study focussed on the role of the primary driver of AR expres-
sion; namely, the transcription factor Sp1 and its binding sites. The GC box in the promoter
immediately upstream of the start of transcription functions was determined to be the principal
Sp1 binding site, although it is not absolutely necessary as additional GC boxes in the 5’UTR-
coding region also participate in stimulation of AR expression; albeit at a lower level. This
implies that the hAR promoter and 5’UTR have a flexible configuration permitting dynamic
remodelling to create the initiation complex. In addition, two novel regulatory elements were
identified in the 5’UTR; an upregulatory GC box and an inhibitory ARS (Fig 9). Importantly,
in both cases the upregulatory GC boxes overlapped inhibitory ARS regions and the transcrip-
tional outcome in PCa cells was determined by the relative amounts of the associated antago-
nistic transcription factors Sp1 and pur-α (Fig 8).
Sp1 belongs to the highly conserved Specificity Protein/Krüppel-like Factor (SP/KLF) tran-
scription factor family and is expressed in all mammalian cells (reviewed in [32]). Although it
was originally considered to function primarily as a constitutive activator of TATA-less pro-
moters e.g. those of housekeeping genes, this view has undergone a radical shift with Sp1 also
participating in more nuanced gene regulation [32]. Importantly, Sp1 is elevated in many
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cancers [32,48] and studies using LNCaP cells show that this leads to increased AR transcrip-
tion [49]. On the other hand, the inhibitory ARS sites that overlap the GC boxes in the two
studied regions can bind the ubiquitously expressed protein pur-α with increased pur-α
expression through the release of epigenic repression in androgen insensitive LNCaP cells lead-
ing to reduced AR expression and concomitant cell proliferation [36], as well as increased sen-
sitivity to bicalutamide [50].
The physical properties of Sp1, pur-α and hnRNP-K mean that their roles in regulating
hAR transcription can be multi-faceted. Sp1 has the ability to form multimers producing DNA
looping that is discernible by electron microscopy [51] thus bringing regulatory elements and
enhancers together. Further levels of complexity are generated by the capacity of Sp1 to associ-
ate with pur-α [52] which can in turn form multimeric complexes with a range of other pro-
teins [53]. Genome-wide studies reveal co-localisation of Sp1 motifs and AR binding sites
suggesting interplay between these proteins and their signalling pathways [54], and it is inter-
esting to note that AR binds to the hAR 5’UTR [34] distal to the regions described here. Sp1
can also interact directly with AR, and in the case of the c-Met promoter in PCa cells this
reduces its upregulatory action [55]. Taken together, the overlapping regulatory elements in
the hAR 5’UTR described here have the ability to not only influence transcription through the
relative binding of competing Sp1 and pur-α transcription factors, but to participate in a
dynamic interplay between multiple proteins to produce numerous outcomes that are heavily
influenced by the confluence of diverse cell signalling pathways.
Fig 8. Variation of transcription factor levels in PCa cells.Western blot analysis of Sp1, pur-α and hnRNP-K protein levels normalised against GAPDH in
the indicated PCa cell lines. The data represent the means ± SEM of at least three independent experiments and statistical significance is: *** p<0.001.
doi:10.1371/journal.pone.0139990.g008
Fig 9. Model for regulation of the human AR gene. The organisation of positive (GC-box) and negative
(ARS, nARE) elements in the promoter and 5’UTR of the AR gene are shown together with the relevant
transcription factors.
doi:10.1371/journal.pone.0139990.g009
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The results of this study highlight the paramount role of Sp1 in driving hAR expression in
PCa cells and, therefore, the appropriateness of targeting Sp1 as a means of suppressing tumour
progression. A diverse range of both synthetic and natural agents that downregulate Sp1
induced AR expression have been shown to be efficacious in a variety PCa cell line and animal
model systems. The anti-tumour antibiotic mithramycin A [29], recent analogues with
improved pharmacological and toxicological properties [56], phenethyl isothiocyanate
(PEITC) present in cruciferous vegetables [57,58] and acetyl-11-keto-beta-boswellic acid
(AKBA) from Boswellia serrata [59] act by disrupting Sp1 binding to GC-boxes, while betulinic
acid from white birch bark [60] and green tea phenols [61] reduce the levels of Sp1 or transacti-
vation activity. However, the finding that DHT-bound AR can also inhibit Sp1 expression [62]
may be a confounding factor when using anti-androgen therapies, as this would be predicted to
lead to elevated Sp1 levels.
There is considerable interest in the mechanisms that control the levels of the AR protein in
different cells and pathophysiological conditions. Our identification of overlapping regulatory
elements that bind antagonistic transcription factors may facilitate rapid changes in expression
of the receptor in response to the relative amounts of Sp1 and pur-α. Reduction of Sp1 or inhi-
bition of its action through the GC boxes detailed here will not only lead to a decrease in AR
mRNA directly, but will also promote the binding of inhibitory pur-α to the super-imposed
ARS sites. This synergistic effect will be especially advantageous in CRPC as pur-α levels are
frequently reduced [36].
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